Interest of the Manual Exploration as a Supplement to the Coelioscopy in the Evaluation of the Resectability of Peritoneal Carcinosis

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02493972

Acronym

CARPEMAN

Enrollment

Registered

2015-07-10

Start date

2015-09-30

Completion date

2019-07-31

Last updated

2019-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer With Peritoneal Carcinosis

Keywords

ovarian cancer, peritoneal carcinosis, manual exploration, surgery, GelPort

Brief summary

This is a Multicenter prospective diagnostic study.

Interventions

PROCEDUREGelPort

Manual exploration of the peritoneal carcinosis by the system GelPort ® with calculation of peritoneal cancer index for evaluation of the resectability

PROCEDURElaparotomy

laparotomy will be performed if indication confirmed by manual exploration

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Over 18 years of age Patient * Woman presenting a peritoneal carcinosis presumed ovarian origin * Coelioscopy (1st intent or recurrence) planned or performed in the last 4 weeks for laparotomy. The peritoneal cancer index of Sugarbaker must be available. * WHO 0 - 2 * Membership in a social security system * Patient having given her written consent

Exclusion criteria

* Male * Contraindication in the coelioscopy * Any associated medical or psychological condition which could compromise the capacity of the patient to participate in the study * Patient deprived of freedom, under guardianship or guardianship

Design outcomes

Primary

Measure	Time frame
evaluate the number of patients with or without laparotomy after evaluation of the resectability by coelioscopy and coelioscopy more manual exploration	1 month after inclusion

Secondary

Measure	Time frame
Number of patients with complications (eventrations, infections, pains) after manual exploration	1 month after inclusion
Number of patients with parietal metastases	1 month after inclusion

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026